Boehringer Ingelheim Korea severs ties with Daewoong

Published: 2012-09-21 06:56:00

Updated: 2012-09-21 06:56:00

Boehringer Ingelheim Korea severed its strategic ties with Daewoong Pharmaceutical over the co-promotion of latter’s over-the-counter (OTC) medicines, it was learned yesterday.

Though the reasons for their sudden severance were not elaborate, industry observers said that the Boehringer Ingelhe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK